Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARTO: Spartalizumab and Low-dose Pazopanib in Refractory or Relapsed Solid Tumors
NCT05210413Phase 2Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- May 2022
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab in solid tumor, sponsored by Centre Hospitalier Universitaire de Bordeaux. Started May 2022; status: active, not recruiting.
02
Drugs
spartalizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05210413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210413.